PPAR-γ in Cushing's disease

Pituitary

Volumn 7, Issue 4, 2004, Pages 265-269

  Heaney, Anthony P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOGLUTETHIMIDE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CYPROHEPTADINE; KETANSERIN; KETOCONAZOLE; METYRAPONE; MITOTANE; OCTREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RITANSERIN; ROSIGLITAZONE; TROGLITAZONE; VALPROIC ACID;

ADRENAL GLAND; ARTICLE; COMORBIDITY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; DIABETES MELLITUS; DISABILITY; DISEASE CONTROL; DRUG MECHANISM; DRUG POTENTIATION; EDEMA; ENDOCRINE SURGERY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LIVER TOXICITY; MENTAL DISEASE; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RADIOTHERAPY; RECURRENCE RISK; SKIN MANIFESTATION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ACTH-SECRETING PITUITARY ADENOMA; ADRENOCORTICOTROPIC HORMONE; CUSHING SYNDROME; HUMANS; LIGANDS; NEOPLASM INVASIVENESS; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 30944431565     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-005-1430-8     Document Type: Article

References (35)

1. Merrill RM, Feuer EJ, Capocaccia R, Mariotto A. Cancer prevalence estimates based on tumor registry data in the SEER program. Int J Epidemiol 2000;29:197-207. 10.1093/ije/29.2.197
2. Central Brain Tumor Registry of the United States (CBTRUS). http://www.cbtrus.org.
3. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro-Oncology 2001;3:141-151. 1:STN:280:DC%2BD38%2Fit1GhtA%3D%3D
4. Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859-3866. 10.1210/jc.84.11.3859
5. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 2000;85:526-529. 10.1210/jc.85.2.526
6. Niemann LK. Medical Therapy of Cushing's Disease. Pituitary 2002;5:77-82.
7. Morris D, Grossman A. The Medical Management of Cushing's Syndrome. Ann NY Acad Sci 2002;970:119-133. 1:CAS:528:DC%2BD38XovFalur0%3D
8. Heaney AP, Melmed S. Pituitary Tumors: Molecular Targets and New Medical Therapies. Nature Reviews Cancer 2004;4:285-295. 10.1038/nrc1320
9. Orth DN. Cushing's syndrome. N Engl J Med 1995;332:791-803. 10.1056/ NEJM199503233321207
10. Simmons NE, Alden TD, Thorner MO, Laws ER Jr. Serum cortisol response to transphenoidal surgery for Cushing disease. J Neurosurg 2001;95:1-8. 1:STN:280:DC%2BD3Mvgt1Clsg%3D%3D
11. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing's disease: A report of 216 cases. Ann Intern Med 1988;109:487-493. 1:STN:280:BieA38rhsF0%3D
12. Barbetta L, Dall'Asta C, Tomei G, Locatelli M, Giovanelli M, Ambrosi B. Assessment of cure and recurrence after pituitary surgery for Cushing's disease. Acta Neurochirurgica (Wien) 2001;143:477-481. 1:STN:280:DC%2BD38%2FislWisg%3D%3D
13. Rees DA, Hanna FW, Davies JS, Miles RG, Vafidis J, Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single center using strict criteria for remission. Clin Endocrinol 2002;56:541-551. 10.1046/j.1365-2265.2002.01511.x
14. Verlhest JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol 1991;35:169-178.
15. Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parmiex M, Roger P. Use of ketaconazole in the treatment of Cushing's diaease and ectopic ACTH syndrome. Clin Endocrinol 1991;34:63-69. 1:STN:280:By6C28fktVw%3D
16. Sonino N, Boscaro M, Merola G, Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985;61:718-722. 1:STN:280:BiqB1cbnslQ%3D
17. McCance DR, Ritchie CM, Sheridan H, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1981;1:573.
18. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-660. 10.1038/347645a0
19. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774. 10.1038/358771a0
20. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514. 1:CAS:528:DyaK1cXit1Gnsrk%3D
21. Heaney AP, Fernando M, Yong W, Melmed S. Functional PPAR-γ receptor represents a novel therapeutic target in Cushing's disease. Nat Med 2002;11:1281-1287.
22. Heaney AP, Fernando M, Melmed S. PPAR-γ receptor ligands: A novel therapy for pituitary tumors. J Clin Invest 2003;111:1381-1388. 10.1172/ JCI200316575
23. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-1669. 1:CAS:528:DyaK28XntlCmtL4%3D
24. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82. 10.1038/34178
25. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998;4:1046-1052. 10.1038/2030
26. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003;9:1-9. 1:CAS:528:DC%2BD3sXnt1Onsg%3D%3D
27. Gruszka A, Kunert-Radek J, Pawlikowski M. Rosiglitazone, PPAR-gamma ligand decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro. Neuro Endocrinol Lett 2005;26:51-54. 1:CAS:528:DC%2BD2MXjtFSqtbk%3D
28. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, Cosci C, Gasperi M, Bartalena L, Martino E. PPAR-γ inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004;150:863-875. 10.1530/eje.0.1500863
29. Alevizaki M, Philippou G, Zapanti L, Alevizaki CC, Anastasiou E, and Mavrikakis M. Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPAR-gamma agonist. The Endocrine Society's 86th Annual Meeting, New Orleans, 2004. P2-453 (abstract).
30. Hull SSA, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol 2004;62:258-262.
31. Heaney AP, Drange MR, Melmed S. Functional PPAR- receptor is a novel target for ACTH-secreting pituitary adenomas (Cushing's disease). The Endocrine Society's 85th Annual Meeting, Philadelphia 2003. OR7-4 (abstract).
32. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Pecoz P. Effects of chronic administration of PPAR-γ receptor ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:1-7. 10.1530/eje.0.1510173
33. Zhu Y, Fernando M, Heaney AP. PPAR-γ binds a putative PPRE in the POMC promoter. The Endocrine Society's 86th Annual Meeting, New Orleans 2004. OR33-6 (abstract).
34. Suri D, Weiss RE. Effect of Pioglitazone on ACTH and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005;90:1340-1346. 1:CAS:528:DC%2BD2MXisVOhsrc%3D
35. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Therap 2002;24:378-396. 1:CAS:528:DC%2BD38XjsV2jtr8%3D